Abstract
This chapter examines some possible future prospects for diagnostic test accuracy studies in dementia, in terms of both potential problems and opportunities. A proposal for the role of pragmatic diagnostic test accuracy studies concludes these considerations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abernethy Holland AJ, Larner AJ. Central nervous system/brain tumour 2-week referral guidelines: prospective 3-year audit. Clin Oncol. 2008;20:201–2.
Aji BM, Larner AJ. Screening for dementia: is one simple question the answer? Clin Med. 2015;15:111–2.
Alzheimer’s Society. Mapping the Dementia Gap: Study produced by Tesco, Alzheimer’s Society and Alzheimer’s Scotland. London: Alzheimer’s Society; 2011.
Alzheimer’s Society. Mapping the Dementia Gap 2012. Progress on improving diagnosis of dementia 2011-2012. London: Alzheimer’s Society; 2013.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). Washington: American Psychiatric Association; 2000.
Amieva H, Jacqmin-Gadda H, Orgogozo JM, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005;128:1093–101.
Arevalo-Rodriguez I, Segura O, Sola I, Bonfill X, Sanchez E, Alonso-Coello P. Diagnostic tools for Alzheimer’s disease dementia and other dementias: an overview of diagnostic test accuracy (DTA) systematic reviews. BMC Neurol. 2014;14(1):183.
Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795–804 [Erratum N Engl J Med. 2012;367:780].
Bonello M, Larner AJ. Is the applause sign useful for diagnosis of dementia and MCI? J Neurol Neurosurg Psychiatry. 2015;86:abstract accepted.
Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49:7–18.
Brunet M. Targets for dementia diagnoses will lead to overdiagnosis. BMJ. 2014;348:g2224.
Brunet MD, McCartney H, Heath I, et al. There is no evidence base for proposed dementia screening. BMJ. 2012;345:e8588.
Burch J, Marson A, Beyer F, et al. Dilemmas in the interpretation of diagnostic accuracy studies on presurgical workup for epilepsy surgery. Epilepsia. 2012;53:1294–302.
Cagliarini AM, Price HL, Livemore ST, Larner AJ. Will use of the Six-Item Cognitive Impairment Test help to close the dementia diagnosis gap? Aging Health. 2013;9:563–6.
Carnero-Pardo C, Espejo-Martinez B, Lopez-Alcalde S, et al. Diagnostic accuracy, effectiveness and cost for cognitive impairment and dementia screening of three short cognitive tests applicable to illiterates. PLoS One. 2011;6(11):e27069.
Department of Health. Prime Minister’s Challenge on Dementia. Delivering major improvements in dementia care and research by 2015. London: Department of Health; 2012a.
Department of Health. Using the Commissioning for Quality and Innovation (CQUIN) payment framework. Guidance on the new national goals 2012–13. London: Department of Health; 2012b.
Doran M, Larner AJ. NICE/SCIE dementia guidance: time to reconsider. Adv Clin Neurosci Rehabil. 2008;8(1):34–5.
Dudas RB, Berrios GE, Hodges JR. The Addenbrooke’s Cognitive Examination (ACE) in the differential diagnosis of early dementias versus affective disorder. Am J Geriatr Psychiatry. 2005;13:218–26.
Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ. 2012;344:e686.
Fox C, Lafortune L, Boustani M, Dening T, Rait G, Brayne C. Screening for dementia – is it a no brainer? Int J Clin Pract. 2013;67:1076–80.
Ghadiri-Sani M, Larner AJ. Head turning sign for diagnosis of dementia and mild cognitive impairment: a revalidation. J Neurol Neurosurg Psychiatry. 2013;84:e2.
Hancock P, Larner AJ. Clinical utility of Patient Health Questionnaire-9 (PHQ-9) in memory clinics. Int J Psychiatry Clin Pract. 2009;13:188–91.
Hancock P, Larner AJ. Cornell Scale for Depression in Dementia (CSDD): clinical utility in a memory clinic. Int J Psychiatry 2015;19:71–4.
Hort J, Bartos A, Pirttila T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol. 2010;17:90–6.
Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911–22.
Jack Jr CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.
Johnson KA, Sperling RA, Gidicsin CM et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5Suppl):S72–83.
Julayanont P, Phillips N, Chertkow H, Nasreddine ZS. Montreal Cognitive Assessment (MoCA): concept and clinical review. In: Larner AJ, editor. Cognitive screening instruments. A practical approach. London: Springer; 2013. p. 111–51.
Knapp M, King D, Romeo R, et al. Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrAtegies for RelaTives) study): a pragmatic randomised controlled trial. BMJ. 2013;347:f6342.
Kotagal V, Langa KM, Plassman BL, et al. Factors associated with cognitive evaluations in the United States. Neurology. 2015;84:64–71.
Larner AJ. A dictionary of neurological signs. Clinical neurosemiology. Dordrecht: Kluwer; 2001.
Larner AJ. Head turning sign: pragmatic utility in clinical diagnosis of cognitive impairment. J Neurol Neurosurg Psychiatry. 2012a;83:852–3.
Larner AJ. Mini-Mental Parkinson (MMP) as a dementia screening test: comparison with the Mini-Mental State Examination (MMSE). Curr Aging Sci. 2012b;5:136–9.
Larner AJ. Screening utility of the “attended alone” sign for subjective memory impairment. Alzheimer Dis Assoc Disord. 2014a;28:364–5.
Larner AJ. Neurological signs of possible diagnostic value in the cognitive disorders clinic. Pract Neurol. 2014b;14:332–5.
Larner AJ. Dementia in clinical practice: a neurological perspective. Pragmatic studies in the cognitive function clinic (2nd edition). London: Springer; 2014c.
Lincoln P, Fenton K, Alessi C, et al. The Blackfriars Consensus on brain health and dementia. Lancet. 2014;383:1805–6.
Mahieux F, Michelet D, Manifacier M-J, Boller F, Fermanian J, Guillard A. Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson’s disease. Behav Neurol. 1995;8:15–22.
Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365:2007–12.
Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385–93.
McAlister FA, Straus SE. Sackett DL, on behalf of the CARE-COAD1 Group: why we need large, simple studies of the clinical examination: the problem and a proposed solution. Lancet. 1999;354:1721–4.
Moyer VA; US Preventive Services Task Force. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:791–7.
Musso M, Cohen AS, Auster TL, McGovern JE. Investigation of the Montreal Cognitive Assessment (MoCA) as a cognitive screener in severe mental illness. Psychiatr Res. 2014;220:664–8.
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.
National Institute for Clinical Excellence. Principles for best practice in clinical audit. Abingdon: Radcliffe Medical Press; 2002.
National Institute for Health and Clinical Excellence/Social Care Institute for Excellence. Dementia: supporting people with dementia and their carers in health and social care. NICE Clinical Guidance 42. London: National Institute for Health and Clinical Excellence (www.nice.org.uk/cG042), 2006.
Noel-Storr AH, McCleery JM, Richard E, et al. Reporting standards for studies of diagnostic test accuracy in dementia: the STARDdem Initiative. Neurology. 2014;83:364–73.
Orrell M, Aguirre E, Spector A, et al. Maintenance cognitive stimulation therapy for dementia: single-blind, multicentre, pragmatic randomised controlled trial. Br J Psychiatry. 2014;204:454–61.
Panicker J, Larner AJ. Two-week wait referrals for CNS cancer – are they working? J Neurol Neurosurg Psychiatry. 2012;83 Suppl 2:A30–1.
Panza F, Solfizzi V, Imbimbo BP, Logroscino G. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return? Expert Opin Biol Ther. 2014;14:1465–76.
Prestia A, Caroli A, Herholz K, et al. Diagnostic accuracy of markers for prodromal Alzheimer’s disease in independent clinical series. Alzheimers Dement. 2013;9:677–86.
Rosser Matthews J. Quantification and the quest for medical certainty. Princeton: Princeton University Press; 1995.
Rotomskis A, Margeviciute R, Germanavicius A, et al. Differential diagnosis of depression and Alzheimer’s disease with the Addenbrooke’s Cognitive Examination-Revised. 2015;submitted.
Sackett DL, Haynes RB. The architecture of diagnostic research. In: Knottnerus JA, editor. The evidence base of clinical diagnosis. London: BMJ Books; 2002. p. 19–38.
Snyder PJ, Kahle-Wrobleski K, Brannan S, et al. Assessing cognition and function in Alzheimer’s disease clinical trials: do we have the right tools? Alzheimers Dement. 2014;10:853–60.
Swainson R, Hodges JR, Galton CJ, et al. Early detection and differential diagnosis of Alzheimer’s disease and depression with neuropsychological tests. Dement Geriatr Cogn Disord. 2001;12:265–80.
Villeda SA, Plambeck KE, Middeldorp J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20:659–63.
Wilson JMG, Jungner G. Principles and practice of screening for disease. Public health paper No. 34. Geneva: World Health Organization; 1968.
Wimo A, Religa D, Spangberg K, Edlund AK, Winblad B, Eriksdotter M. Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry. Int J Geriatr Psychiatry. 2013;28:1039–44.
Wimo A, Ballard C, Brayne C, et al. Health economic evaluation of treatments for Alzheimer’s disease: impact of new diagnostic criteria. J Intern Med. 2014;275:304–16.
Wolfsgruber S, Jessen F, Wiese B, et al. The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy. Am J Geriatr Psychiatry. 2014;22:1017–28.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Larner, A.J. (2015). Future Prospects for Diagnostic Test Accuracy Studies in Dementia. In: Diagnostic Test Accuracy Studies in Dementia. Springer, Cham. https://doi.org/10.1007/978-3-319-16697-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-16697-1_6
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16696-4
Online ISBN: 978-3-319-16697-1
eBook Packages: MedicineMedicine (R0)